4 January 2017 CES2017-P-002 v0.9

Commercially ConfidentialDigital Health Summit

Jonathan Minko

Validating theCollective PictureWhat Digital Biomarkers Mean for Healthcare

Systems and Personalized Medicine

4 January 2017 CES2017-P-002 v0.92Commercially Confidential

At Cambridge Consultants, we help innovative companies develop

products and systems across industries.

4 January 2017 CES2017-P-002 v0.93Commercially Confidential

What areBiomarkers?

4 January 2017 CES2017-P-002 v0.94Commercially Confidential

Digital BiomarkersThere is a plethora of lifestyle data that are likely to inform and manage health state.

4 January 2017 CES2017-P-002 v0.95Commercially Confidential

Data is accumulated from personal devices

constantly & everywhere.Information can be extracted from data to build

intelligence.

4 January 2017 CES2017-P-002 v0.96Commercially Confidential

$263 million invested in

2016in wearable and bio-sensing digital health ventures.

4 January 2017 CES2017-P-002 v0.97Commercially Confidential

shorten drug trials

Improve clinical trials.Using digital markers may enable us to:

lower recruitment better quantitative end points

4 January 2017 CES2017-P-002 v0.98Commercially Confidential

CV

For B

iom

arke

rs<3

0%<1

0%rare event

detection or exploratory use

candidate for validation &

inclusion in panels

reliability or intended use

lacking for validation

lower weighted in panels fit for

purpose studies

Biomarker Weighting

Level of FDA ControlsConsumer Class III Device

4 January 2017 CES2017-P-002 v0.99Commercially Confidential

Manage chronic disease.

4 January 2017 CES2017-P-002 v0.910Commercially Confidential

Paths to market:

Launch with a Minimum Viable Product (MVP), start gathering data

Build brand awareness and improve patient

engagement

Work towards a more robust solution that can give the

required claims for longer term

Provide services as a gateway to clinical validated digital biomarkers

4 January 2017 CES2017-P-002 v0.911Commercially Confidential

Provide value from data.

Data Feed

Valu

e

provide information

nudge behavior

Descriptive Analytics

(What happened?)

Diagnostic Analytics(Why did it happen?)

Predictive Analytics(What will happen?)

Prescriptive Analytics

(How can we make it happen?)

From hindsight to insight to foresight.

4 January 2017 CES2017-P-002 v0.912Commercially Confidential

Alternative business modelThrough tracking and improving outcome.

*CMS expects 50% of all payments to be via alternative models by 2018

consumer healthcare

applications

care networks

virtual care services

medical device manufactures

*

4 January 2017 CES2017-P-002 v0.913Commercially Confidential

Think Partnership.

4 January 2017 CES2017-P-002 v0.914Commercially Confidential

Hitting the sweet spot.

science, technology &

systems

Requirements for deploying a successful, viable biomarker solution.

market proposition

business model

4 January 2017 CES2017-P-002 v0.915Commercially Confidential

Now is the time!

4 January 2017 CES2017-P-002 v0.916Commercially Confidential

NEW DELHITOKYO

SINGAPORE

CAMBRIDGE

BOSTON

>700 engineers, scientists, designers and consultants developing breakthrough technologies

SEATTLE

SANFRANCISCO